Orchard Therapeutics plc - ADR

0.00 (-0.09%)
Products, Layoffs, Earnings Announcements

Orchard Therapeutics Says Plans To Seek Strategic Alternatives For Primary Immunodeficiency Programs

Published: 03/30/2022 11:17 GMT
Orchard Therapeutics plc - ADR (ORTX) - Orchard Therapeutics Extends Runway Into 2024, Focusing Hsc Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform.
Plan to Seek Strategic Alternatives for Primary Immunodeficiency Programs, Including Otl-103 in Was.
Refined Portfolio and 30% Proposed Workforce Reduction Extend Cash Runway Into 2024.
Will Continue Its Investment in Libmeldy (atidarsagene Autotemcel) / Otl-200 for Metachromatic Leukodystrophy (mld).
Orchard Therapeutics - to Continue to Advance Development of Otl-203 for Mucopolysaccharidosis Type I Hurler's Syndrome & Otl-201 for Mucopolysaccharidosis Type Iiia.
Believes Path to a Potential Bla Filing of Otl-103 Program May Require Additional Time and Further Investment.
Orchard Therapeutics - Proposed to Reduce Its Current Workforce by About 30%, Which Will Result in a Restructuring Charge in 2022.
Expects Research and Development Expenses to Decline Beginning in Q2 2022 Due to Portfolio Updates and Workforce Reduction.
Qtrly Net Loss per Share, Basic and Diluted$0.29.
Q4 Earnings per Share View $-0.28 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $3.5 Million
Adjusted EPS is expected to be -$0.26

Next Quarter Revenue Guidance is expected to be $3.04 Million
Next Quarter EPS Guidance is expected to be -$0.21

More details on our Analysts Page.